Successful use of recombinant factor VIIa in pelvic fracture haemorrhage.
Recombinant factor VIIa is a novel haemostatic agent and was originally developed to treat haemophilia patients. Successful use of the factor in a 30-year-old male patient with pelvic fracture haemorrhage is being described by the authors.